期刊文献+

卵巢癌原癌基因c-erbB-2扩增与预后的关系 被引量:4

The relation between prognosis and amplification ofthe C-erbB-2 (HER-2/neu) proto-oncogene in ovariancarcinomas
原文传递
导出
摘要 提取卵巢癌组织DNA,限制性内切酶EcoRI酶解后,经过凝胶电泳,Southern转移至硝酸纤维膜,与 ̄(32)P标记的c-erbB-2探针进行分子杂交,放射自显影。结果显示,26例上皮性卵巢癌中,8例(30.8%)出现了该基因的扩增。这8例均为晚期(III~IV期)肿瘤病人,其中5例在术后2~4个月内死亡,说明该基因的扩增在晚期卵巢癌中出现,与病人预后不良有关,该基因的激活在卵巢癌的发生过程中亦起一定的作用。 -erbB-2 (HER-2/neu) proto-oncogene is mainlyexpressed in epithelial tissue and activated due to itsamplification. Amplification of the C-erbB-2 proto-oncogene is associated with poor prognosis in humanovarian cancer. We exairJined whether arnplificationof C-erbB-2 is common in ovarian carcinoma or is as-sociated with poor prognosis. The DNA of ovariancarcinoma was extracted and consequently digestedwith restriction endonuclease EcoRI, electrophoresedin 0.8% agarose gels and blotted onto nitrocelluiosefilter with Southern transfering method. It was hy-bridized with a 32p-labelled C-erbB-2 probe and sub-sequently underwent autoradiography, It was shownthat the C-erbB-2 (HER-2/neu) gene was amplifiedin 8 of 26 human ovarian carcinornas (30.8%). Clin-ically the 8 patients with the amplified C-erbB-2 werein their advanced stage(III-IV). Five of the patientsdied from 2 to 4 months after operation. These find-ings sdggest that amplification of the C-erbB-2 geneniay play a role in the patnogenesis of ovarian carci-noma, it is frequently observed in advanced ovariancarcinoma and associated with poor prognosis forthese patients.
出处 《中华医学杂志》 CAS CSCD 北大核心 1994年第11期683-685,共3页 National Medical Journal of China
基金 国家自然科学基金
关键词 卵巢肿瘤 DNA探针 扩增 癌基因 预后 Ovarian neoplasms Genes am-plificatian DNA probes
  • 相关文献

同被引文献16

  • 1李广太,焦书竹.卵巢癌neu癌基因的研究进展[J].中华妇产科杂志,1995,30(3):176-179. 被引量:3
  • 2吴令英.c-erbB-2癌基因与卵巢癌[J].国外医学(妇产科学分册),1996,23(4):204-207. 被引量:2
  • 3周国荣.与妇科恶性肿瘤相关的癌基因[J].国外医学(遗传学分册),1996,19(2):77-78. 被引量:5
  • 4Dodwin AK, Teataa JR, handle LM et al. Spontrneous transformation of ratovarian cancer surface epithepial cells implicates repeated ovalution in ovarion cancer etiology and is associated with clonal cytogenetic changes. J Natl Cancer Inst, 1992, 61:829.
  • 5Anreder MB,Freeman SM ,Merogi A et al. P53,C-erbB2,and PCN Astatus in benign, proliferative and maligmant ovarian surface epithelial neoplasms: a study of 75 cases. Arch Pathol Lab Med,1999, 123:310.
  • 6Felip E, Del Campo JM, Rugbio D et al. Overexpression of C erbB2 in epithelail ovarian cancer. Cancer, 1995, 75:2 147.
  • 7Yonemura Y. Expression of C erbB2 oncoprotein in gastric carcinomas. Cancer, 1991, 67:2 914.
  • 8Havrilesky L J, Alvares AA, Whitaker RS, et al. Loss of expression of the Pl6 tumor suppressor gene is more frequent in advanced ovarian cancers lacking P53 mutations [J]. Gynecol Oncol, 2001,83: 491.
  • 9Kajiwara Y, Yamasaki F, Hama S et al. Expression of surviving in astrocytic tumors. Cancer, 2003, 98 (4): 1077.
  • 10Kakar SS. Molecular clining genomic organization and identfication,of the promoter for the human pituitary tumor transforming gene(PTTG) .Gene, 1999, 240:317.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部